Asthma exacerbations may be halved in patients at high risk of serious asthma-related morbidity and mortality by using omalizumab.
This was the finding of a meta-analysis of three randomized, double-blind placebo-controlled trials involving 1412 patients with moderate or severe allergic asthma. All patients in the study required daily inhaled steroids.
The anti-immunoglobulin E antibody, omalizumab was given, as add-on therapy, subcutaneously every two or four weeks at a total four-weekly dose of at least 0.016mg/kg/IgE. All studies had a steroid-stable phase, followed by a steroid-reduction phase, and then two-studies had an extension phase.
Professor Stephen Holgate, a staff professor at the University of Southampton School of Medicine, said, "Overall, the number of patients with at least one significant asthma exacerbation episode during the steroid-stable phase was reduced from 35 percent with placebo to 18 percent with omalizumab".
Mean significant asthma exacerbation episodes were 1.56 per patient-year for the placebo group and 0.69 per patient-year for the omalizumab group. This represented a 56 percent reduction with omalizumab (P=0.007).
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!